Back to top
more

China SXT Pharmaceuticals (SXTC)

(Delayed Data from NSDQ)

$0.49 USD

0.49
115,712

+0.01 (2.74%)

Updated Nov 8, 2024 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (69 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Balance Sheet

Fiscal Year End for China SXT Pharmaceuticals, Inc falls in the month of March.

All items in Millions except Per Share data.

3/31/2024 3/31/2023 3/31/2022 3/31/2021 3/31/2020
Assets          
Cash & Equivalents 12 17 16 13 7
Receivables 1 1 3 5 5
Notes Receivable 0 0 2 2 2
Inventories 1 1 1 1 1
Other Current Assets 0 0 1 3 5
Total Current Assets 14 20 22 23 20
Net Property & Equipment 0 1 2 2 2
Investments & Advances 8 9 9 9 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 0 0 0 0 0
Total Assets 23 30 34 35 22
Liabilities & Shareholders Equity 3/31/2024 3/31/2023 3/31/2022 3/31/2021 3/31/2020
Notes Payable 0 0 0 0 0
Accounts Payable 1 1 1 1 2
Current Portion Long-Term Debt 2 3 2 0 7
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 3 3 4 3 2
Income Taxes Payable 1 1 1 1 1
Other Current Liabilities 1 5 9 13 0
Total Current Liabilities 9 15 17 19 12
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 0 0 0 0 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 9 15 17 19 12
Shareholders Equity 3/31/2024 3/31/2023 3/31/2022 3/31/2021 3/31/2020
Preferred Stock 0 0 0 0 0
Common Stock (Par) 4 1 0 0 0
Capital Surplus 35 36 31 25 17
Retained Earnings -25 -22 -16 -10 -7
Other Equity -1 0 1 1 -1
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 14 15 16 16 9
Total Liabilities & Shareholder's Equity 23 30 34 35 22
Total Common Equity 14 15 16 16 9
Shares Outstanding 0.40 0.40 0.00 0.00 0.00
Book Value Per Share 34.83 36.73 16.42 15.96 9.40

Fiscal Year End for China SXT Pharmaceuticals, Inc falls in the month of March.

All items in Millions except Per Share data.

9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023
Assets          
Cash & Equivalents -99,999 -99,999 12 -99,999 -99,988
Receivables NA NA 1 NA 1
Notes Receivable NA NA 0 NA NA
Inventories NA NA 1 NA 0
Other Current Assets NA NA 0 NA 0
Total Current Assets NA NA 14 NA 14
Net Property & Equipment NA NA 0 NA 1
Investments & Advances NA NA 8 NA NA
Other Non-Current Assets NA NA 0 NA NA
Deferred Charges NA NA 0 NA NA
Intangibles NA NA 0 NA 0
Deposits & Other Assets NA NA 0 NA NA
Total Assets NA NA 23 NA 15
Liabilities & Shareholders Equity 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023
Notes Payable NA NA 0 NA NA
Accounts Payable NA NA 1 NA 1
Current Portion Long-Term Debt NA NA 2 NA 3
Current Portion Capital Leases NA NA 0 NA NA
Accrued Expenses NA NA 3 NA 3
Income Taxes Payable NA NA 1 NA 1
Other Current Liabilities NA NA 1 NA 1
Total Current Liabilities NA NA 9 NA 9
Mortgages NA NA 0 NA NA
Deferred Taxes/Income NA NA 0 NA NA
Convertible Debt NA NA 0 NA NA
Long-Term Debt NA NA 0 NA 0
Non-Current Capital Leases NA NA 0 NA NA
Other Non-Current Liabilities NA 0 NA NA
Minority Interest (Liabilities) NA NA 0 NA NA
Total Liabilities NA NA 9 NA 10
Shareholders Equity 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023
Preferred Stock NA NA 0 NA NA
Common Stock (Par) NA NA 4 NA 1
Capital Surplus NA NA 35 NA 36
Retained Earnings NA NA -25 NA -31
Other Equity NA NA -1 NA -1
Treasury Stock NA NA 0 NA NA
Total Shareholder's Equity NA NA 14 NA 5
Total Liabilities & Shareholder's Equity NA NA 23 NA 15
Total Common Equity 0 0 14 0 100,004
Shares Outstanding 4.00 0.40 0.40 0.40 0.40
Book Value Per Share 0.00 0.00 34.83 0.00 250,010.20